for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tyme Technologies Inc

TYME.OQ

Latest Trade

1.02USD

Change

0.02(+2.00%)

Volume

63,751

Today's Range

1.01

 - 

1.03

52 Week Range

0.85

 - 

4.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

TYME Technologies Inc Provides Business Update And Announces Fiscal First Quarter 2022 Financial

Aug 10 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME TECHNOLOGIES, INC. PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL FIRST QUARTER 2022 FINANCIAL AND OPERATING RESULTS.Q1 ADJUSTED LOSS PER SHARE $0.03.QTRLY LOSS PER SHARE $0.03.TYME TECHNOLOGIES - IDENTIFYING BREAST CANCER, SECOND-LINE PANCREATIC CANCER, HIGH-RISK SARCOMAS AS PRIORITY CLINICAL SETTINGS.

Tyme Technologies Inc Reports Fiscal Year 2021 Financial Results

June 10 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME TECHNOLOGIES, INC. COMPLETES STRATEGIC REVIEW, ANNOUNCES OASIS BREAST TRIAL WITH GEORGETOWN UNIVERSITY, AND REPORTS FISCAL YEAR 2021 FINANCIAL RESULTS.

Tyme Announces Richie Cunningham As New Chief Executive Officer

Feb 4 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER FISCAL 2021 FINANCIAL AND OPERATING RESULTS.TYME TECHNOLOGIES INC - ANNOUNCED RICHIE CUNNINGHAM AS NEW CHIEF EXECUTIVE OFFICER.TYME TECHNOLOGIES INC - AS OF Q3 ENDED DECEMBER 31, 2020, COMPANY HAD APPROXIMATELY $13.5 MILLION IN CASH AND CASH EQUIVALENTS.TYME TECHNOLOGIES INC - TYME'S OPERATIONAL CASH BURN RATE FOR Q3 OF FISCAL YEAR 2021 WAS $5.9 MILLION COMPARED TO $6.6 MILLION FOR Q2 OF FISCAL YEAR 2021.TYME TECHNOLOGIES - CONTINUES TO ANTICIPATE ITS QUARTERLY CASH USAGE WILL AVERAGE APPROXIMATELY $6.0 TO $6.5 MILLION PER QUARTER DURING FISCAL YEAR 2021.TYME TECHNOLOGIES INC - FULL ENROLLMENT IN TYME-88-PANC PIVOTAL TRIAL NOT EXPECTED BEFORE CALENDAR YEAR 2022.TYME TECHNOLOGIES INC - CONTINUE TO ADVANCE ENROLLMENT IN HOPES SARCOMA PHASE II TRIAL; EXPECT DATA READOUT IN CALENDAR YEAR 2021.TYME TECHNOLOGIES - EXPECTS TO INITIATE PROOF-OF-CONCEPT TRIAL TO EVALUATE TYME-19 AS A POTENTIAL NEW APPROACH AGAINST COVID-19 IN CALENDAR YEAR 2021.

Tyme Technologies Inc Says On November 23, Appointed Richard Cunningham As New CEO

Nov 30 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME TECHNOLOGIES INC - ON NOVEMBER 23, APPOINTED RICHARD CUNNINGHAM AS NEW CEO, EFFECTIVE NOVEMBER 24, 2020.TYME TECHNOLOGIES INC - BOARD ALSO APPOINTED CUNNINGHAM TO SERVE ON BOARD TO FILL A VACANCY AS A CLASS II DIRECTOR.

Tyme Provides Business Update And Announces Q2 Fiscal 2021 Financial And Operating Results

Nov 12 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME PROVIDES BUSINESS UPDATE AND ANNOUNCES SECOND QUARTER FISCAL 2021 FINANCIAL AND OPERATING RESULTS.

Tyme Technologies - On September 15, Ben R. Taylor Gave Notice Of His Resignation From His Position As President And Chief Financial Officer Of Tyme

Sept 21 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME TECHNOLOGIES - ON SEPTEMBER 15, BEN R. TAYLOR GAVE NOTICE OF HIS RESIGNATION FROM HIS POSITION AS PRESIDENT AND CHIEF FINANCIAL OFFICER OF TYME.TYME TECHNOLOGIES INC - HAS COMMENCED A SEARCH FOR TAYLOR'S REPLACEMENT AS CHIEF FINANCIAL OFFICER.TYME TECHNOLOGIES INC - BARBARA GALAINI HAS BEEN APPOINTED ACTING PRINCIPAL FINANCIAL OFFICER, TO BE EFFECTIVE ON SEPTEMBER 30, 2020.

Tyme Announces Orphan Drug Designation For SM-88 For Patients With Pancreatic Cancer

Aug 3 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME ANNOUNCES ORPHAN DRUG DESIGNATION FOR SM-88 AS POTENTIAL TREATMENT FOR PATIENTS WITH PANCREATIC CANCER.TYME TECHNOLOGIES - FDA GRANTED ORPHAN DRUG DESIGNATION FOR SM-88 (RACEMETYROSINE), AS POTENTIAL TREATMENT FOR PATIENTS WITH PANCREATIC CANCER.

Tyme Technologies Continues To Anticipate Its Qtrly Cash Usage Will Average Between $7-8 Million 2021

July 13 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME PROVIDES BUSINESS UPDATE AND ANNOUNCES PRELIMINARY FIRST QUARTER FISCAL 2021 FINANCIAL AND OPERATING RESULTS.TYME TECHNOLOGIES INC - AS OF JUNE 30, HAD ABOUT $21.3 MILLION IN CASH AND CASH EQUIVALENTS.TYME TECHNOLOGIES - CONTINUES TO ANTICIPATE ITS QUARTERLY CASH USAGE WILL AVERAGE BETWEEN $7.0 TO 8.0 MILLION PER QUARTER FOR FISCAL YEAR 2021.

Tyme Announces Q4 And Fiscal Year 2020 Financial And Operating Results

May 20 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL AND OPERATING RESULTS.TYME TECHNOLOGIES INC - TYME-88-PANC PIVOTAL TRIAL ENROLLING PATIENTS USING ORAL SM-88 AS A POTENTIAL TREATMENT FOR THIRD-LINE PANCREATIC CANCER.TYME TECHNOLOGIES INC - EXPECTS ACTUAL NET QUARTERLY CASH BURN TO BE LOWER THAN OPERATIONAL CASH BURN AFTER ACCOUNTING FOR CASH INFLOWS.TYME - BELIEVES CASH, CASH EQUIVALENTS AS OF QUARTER END, ANTICIPATED ACCESS TO ADDITIONAL CAPITAL, IS ADEQUATE TO FUND SOME CURRENT TRIALS.

Tyme Technologies Reports Q3 Adj Loss Per Share Of $0.05

Feb 5 (Reuters) - Tyme Technologies Inc <TYME.O>::TYME ANNOUNCES THIRD QUARTER FISCAL 2020 FINANCIAL AND OPERATING RESULTS.Q3 ADJUSTED LOSS PER SHARE $0.05.QTRLY BASIC AND DILUTED LOSS PER COMMON SHARE$0.06.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up